aid: coregen
name: CoRegen
description: 'CoRegen, Inc. (CoRegen Science) is a clinical-stage biopharmaceutical company
  in Houston, Texas developing adoptive cell therapies for aggressive solid tumors. Its
  platform, licensed exclusively from the O''Malley Lab at Baylor College of Medicine,
  uses CRISPR gene editing to knock out the SRC-3 steroid receptor coactivator gene in
  regulatory T (Treg) cells, reprogramming them from immunosuppressors into tumor-killing
  effectors. The lead program, CRG-150, received FDA IND clearance for a first-in-human
  Phase 1/2a trial in advanced solid tumors, and the underlying science won the 2023
  Cozzarelli Prize. CoRegen is a therapeutics organization, not a software company: it
  publishes a nine-page marketing and science site (about, the science, preclinical studies,
  pipeline, publications, leadership, news, careers, contact) and no developer program,
  API, SDK, or machine-readable specification of any kind.'
image: https://static.wixstatic.com/media/6bbba7_0128eda3793342649faba3890102b461~mv2.png
url: https://raw.githubusercontent.com/api-evangelist/coregen/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-11'
modified: '2026-08-11'
tags:
- Company
- Biotechnology
- Life Sciences
- Oncology
- Cell Therapy
- Immunotherapy
- Gene Editing
- Pharmaceuticals
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/coregen-domain-security.yml
- type: LLMsTxt
  url: llms/coregen-llms.txt
- type: Website
  url: https://www.coregen.com/
- type: About
  url: https://www.coregen.com/about
- type: Science
  name: The Science
  url: https://www.coregen.com/thescience
- type: Research
  name: Preclinical Studies
  url: https://www.coregen.com/preclinicalstudies
- type: Product
  name: Pipeline
  url: https://www.coregen.com/pipeline
- type: Publications
  url: https://www.coregen.com/publications
- type: Team
  name: Leadership
  url: https://www.coregen.com/leadership
- type: Newsroom
  name: News
  url: https://www.coregen.com/news
- type: Careers
  url: https://www.coregen.com/careers
- type: Contact
  url: https://www.coregen.com/contact
- type: PrivacyPolicy
  url: https://www.coregen.com/privacy-policy
- type: TermsOfService
  url: https://www.coregen.com/terms-and-conditions
- type: SecondaryMarket
  name: Forge Global
  url: https://forgeglobal.com/coregen_stock/
x-enrichment:
  date: '2026-08-11'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    CoRegen is a clinical-stage cancer cell-therapy company, not a software company —
    coregen.com is a nine-page Wix marketing and science site (about, the science,
    preclinical studies, pipeline, publications, leadership, news, careers, contact)
    where /developers, /docs, /api, /graphql, /mcp, /openapi.json and /llms.txt all
    return a real 404 (verified against a control path that also 404s), every
    /.well-known/* path returns a hard Wix HTTP 400 error page, and no developer
    subdomain (api./docs./developer./mcp.coregen.com) resolves in DNS.
  evidence:
    - url: https://www.coregen.com/
      status: 200
    - url: https://www.coregen.com/developers
      status: 404
    - url: https://www.coregen.com/openapi.json
      status: 400
    - url: https://www.coregen.com/llms.txt
      status: 404
    - url: https://www.coregen.com/api
      status: 404
    - url: https://www.coregen.com/.well-known/agent-card.json
      status: 400
    - url: https://www.coregen.com/.well-known/security.txt
      status: 400
    - url: https://www.coregen.com/definitely-not-a-real-path-abc123xyz
      status: 404
  checked: '2026-08-11'